Ncm460

A total of 56 CC primary patients were enrolled from The First College of Clinical Medical Science, China Three Gorges University, between 06/2015 and 12/2020. Clinicopathological characteristics of these 56 patients are shown in Table A1. The inclusion criteria are as follows: patients were allowed to collect the tumor tissues and adjacent (>3 cm) normal tissues and patients received the FOLFOX regimen after the surgery. Tumor and normal tissues were confirmed using immunohistochemistry. The exclusion criteria are as follows: patients with other tumors, patients with autoimmune diseases, and patients with CC family history. Overall survival was obtained from the postoperative follow-up for 5 years, and overall survival time was defined as the time from surgery to death or the last follow-up.
Four CC cell lines HCT116 (#91091005), SW480 (#87092801), SW620 (#87051203), and LoVo (#87060101) were collected from ECACC (Salisbury, UK), and one normal colonic epithelial cell line NCM460 (#75) was collected from LONZA (Basel, Switzerland). All cell lines were normally cultured according to the suggestion.

A normal human colon epithelial cell line, NCM460, was obtained from Lonza (Basel, Switzerland) and cultured in DMEM: F12 medium (Gibco, Waltham, MA, USA) supplemented with 10% FBS (Invitrogen, Waltham, MA, USA). Four human colorectal cancer cell lines, HCT116 (p53^wt; CCL-247™), RKO (p53^wt; CRL-2577™), LoVo (p53^wt; CCL-229™), and SW480 (p53^mut; CCL-228™), were procured from ATCC (Manassas, VA, USA). HCT116 cells were cultured in McCoy’s 5a medium modified (Gibco) supplemented with 10% FBS (Invitrogen, CA, USA). RKO cells were cultured in an Eagle’s Minimum Essential Medium (Gibco) supplemented with 10% FBS (Invitrogen). LoVo cells were cultured in F-12K medium (ATCC) supplemented with 10% FBS (Invitrogen). SW480 cells were cultured in Leibovitz’s L-15 medium (ATCC) supplemented with 10% FBS (Invitrogen). All cells were cultured at 37°C in 5% CO₂.